Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for NVCR

Stock NameNovocure Ltd
TickerNVCR(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINJE00BYSS4X48
LEI213800YPP55UMHWA4826

Show aggregate NVCR holdings

News associated with NVCR

NovoCure (NASDAQ:NVCR) Shares Gap Up Following Insider Buying Activity
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $12.28, but opened at $13.65. NovoCure shares last traded at $13.03, with a volume of 543,802 shares trading hands. Specifically, CEO Ashley Cordova acquired 81,550 shares of the […] - 2025-09-10 02:26:51
Analysts Set NovoCure Limited (NASDAQ:NVCR) Price Target at $28.79
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average […] - 2025-08-21 04:44:51
Novocure Submits Premarket Approval Application To FDA For TTFields Therapy In Pancreatic Cancer
(RTTNews) - Novocure (NVCR) Wednesday said it has submitted a premarket approval application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. - 2025-08-20 08:50:20
TD Asset Management Inc Sells 204,942 Shares of NovoCure Limited (NASDAQ:NVCR)
TD Asset Management Inc decreased its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 81.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 48,212 shares of the medical equipment provider’s stock after selling 204,942 shares during the period. TD Asset Management Inc’s holdings in NovoCure […] - 2025-08-05 04:37:19
Y Intercept Hong Kong Ltd Has $419,000 Stock Position in NovoCure Limited (NASDAQ:NVCR)
Y Intercept Hong Kong Ltd raised its stake in NovoCure Limited (NASDAQ:NVCR – Free Report) by 25.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,492 shares of the medical equipment provider’s stock after buying an additional 4,723 shares during […] - 2025-07-29 05:56:52
NovoCure (NASDAQ:NVCR) Receives “Equal Weight” Rating from Wells Fargo & Company
Wells Fargo & Company reissued their equal weight rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report released on Friday morning, Marketbeat reports. The firm currently has a $14.50 target price on the medical equipment provider’s stock, down from their previous target price of $40.00. Other analysts also recently issued reports about […] - 2025-07-28 04:18:52
Bank of New York Mellon Corp Purchases 2,062 Shares of NovoCure Limited (NASDAQ:NVCR)
Bank of New York Mellon Corp grew its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 324,592 shares of the medical equipment provider’s stock after acquiring an […] - 2025-07-25 04:35:07
32,179 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by Jennison Associates LLC
Jennison Associates LLC acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,179 shares of the medical equipment provider’s stock, valued at approximately $573,000. Several other large investors also […] - 2025-07-23 06:20:54
Teacher Retirement System of Texas Acquires 3,123 Shares of NovoCure Limited (NASDAQ:NVCR)
Teacher Retirement System of Texas raised its holdings in NovoCure Limited (NASDAQ:NVCR – Free Report) by 5.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 62,375 shares of the medical equipment provider’s stock after purchasing an additional 3,123 shares during the quarter. Teacher Retirement System of Texas’ holdings in NovoCure were worth […] - 2025-07-14 04:56:53
LADENBURG THALM/SH SH Begins Coverage on NovoCure (NASDAQ:NVCR)
LADENBURG THALM/SH SH began coverage on shares of NovoCure (NASDAQ:NVCR – Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $30.00 price target on the medical equipment provider’s stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 64.93% from the […] - 2025-07-10 04:01:26
California State Teachers Retirement System Sells 635 Shares of NovoCure Limited (NASDAQ:NVCR)
California State Teachers Retirement System reduced its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,389 shares of the medical equipment provider’s stock after selling 635 shares during the quarter. California […] - 2025-06-06 05:42:57
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […] - 2025-06-04 03:06:44
BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR)
BNP Paribas Financial Markets decreased its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 83.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,555 shares of the medical equipment provider’s stock after selling 147,371 shares during the period. BNP Paribas Financial Markets’ holdings in NovoCure were worth $851,000 as of […] - 2025-05-22 04:38:53
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Deutsche Bank AG
Deutsche Bank AG lifted its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 20.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,327 shares of the medical equipment provider’s stock after acquiring an additional 33,293 shares during the quarter. Deutsche Bank […] - 2025-05-19 05:06:55
Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR)
Tower Research Capital LLC TRC trimmed its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,034 shares of the medical equipment provider’s stock after selling 6,669 shares […] - 2025-05-12 04:50:52
NovoCure (NASDAQ:NVCR) and Meihua International Medical Technologies (NASDAQ:MHUA) Head to Head Survey
Meihua International Medical Technologies (NASDAQ:MHUA – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Institutional and Insider Ownership 1.2% of […] - 2025-05-06 02:09:04
Why NovoCure Stock Skyrocketed This Week
Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. - 2025-04-25 14:21:57
Bank of Montreal Can Acquires New Shares in NovoCure Limited (NASDAQ:NVCR)
Bank of Montreal Can purchased a new position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 8,183 shares of the medical equipment provider’s stock, valued at approximately $244,000. Other institutional investors have also made changes to their positions in the company. Tidal Investments LLC […] - 2025-04-25 05:08:56
Piper Sandler Issues Pessimistic Forecast for NovoCure (NASDAQ:NVCR) Stock Price
NovoCure (NASDAQ:NVCR – Get Free Report) had its price objective reduced by analysts at Piper Sandler from $42.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would indicate a potential upside of 83.29% from the stock’s current […] - 2025-04-25 04:31:12
NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com
NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday. Other research analysts have also recently issued research reports about the stock. Piper Sandler reduced their price target on shares of NovoCure from $42.00 to $34.00 and set an “overweight” […] - 2025-04-25 03:10:53
NovoCure Surpasses Q1 Expectations
NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s e - 2025-04-24 10:25:13
Legal & General Group Plc Reduces Stake in NovoCure Limited (NASDAQ:NVCR)
Legal & General Group Plc cut its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 14.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 157,758 shares of the medical equipment provider’s stock after selling 26,654 shares during the quarter. Legal & General Group Plc’s holdings in NovoCure were worth $4,701,000 […] - 2025-04-22 05:44:56
Summit Investment Advisors Inc. Raises Stock Holdings in NovoCure Limited (NASDAQ:NVCR)
Summit Investment Advisors Inc. boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,141 shares of the medical equipment provider’s stock after acquiring an additional 708 shares […] - 2025-04-21 04:56:57
StockNews.com Downgrades NovoCure (NASDAQ:NVCR) to Sell
NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday. Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares […] - 2025-04-11 05:18:59
Pictet Asset Management Holding SA Boosts Stake in NovoCure Limited (NASDAQ:NVCR)
Pictet Asset Management Holding SA boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,919 shares of the medical equipment provider’s stock after acquiring an additional […] - 2025-04-10 05:37:15
21,600 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS acquired a new stake in NovoCure Limited (NASDAQ:NVCR – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,600 shares of the medical equipment provider’s stock, valued at approximately $644,000. A number of other hedge funds have also modified their holdings of […] - 2025-04-02 05:16:54
NovoCure Limited (NASDAQ:NVCR) Receives $35.80 Consensus PT from Analysts
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective […] - 2025-03-24 04:40:48
NovoCure (NASDAQ:NVCR) Raised to “Hold” at StockNews.com
NovoCure (NASDAQ:NVCR – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday. Other analysts have also issued reports about the stock. Wedbush reissued a “neutral” rating and set a $29.00 target price on shares of NovoCure in a […] - 2025-03-20 03:44:55
Charles Schwab Investment Management Inc. Purchases 11,771 Shares of NovoCure Limited (NASDAQ:NVCR)
Charles Schwab Investment Management Inc. boosted its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 1.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 836,214 shares of the medical equipment provider’s stock after buying an additional 11,771 shares during the period. […] - 2025-03-19 05:52:57
SBI Securities Co. Ltd. Invests $70,000 in NovoCure Limited (NASDAQ:NVCR)
SBI Securities Co. Ltd. acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,341 shares of the medical equipment provider’s stock, valued at approximately $70,000. Several other institutional investors have also added to or reduced their stakes in the stock. Brooklyn Investment Group bought […] - 2025-03-10 06:07:07

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) NVCR holdings

DateNumber of NVCR Shares HeldBase Market Value of NVCR SharesLocal Market Value of NVCR SharesChange in NVCR Shares HeldChange in NVCR Base ValueCurrent Price per NVCR Share HeldPrevious Price per NVCR Share Held
2025-11-11 (Tuesday)71,784USD 851,358USD 851,358
2025-11-10 (Monday)71,784NVCR holding increased by 185USD 809,006NVCR holding increased by 27145USD 809,006185USD 27,145 USD 11.27 USD 10.92
2025-11-07 (Friday)71,599USD 781,861NVCR holding decreased by -25060USD 781,8610USD -25,060 USD 10.92 USD 11.27
2025-11-06 (Thursday)71,599NVCR holding increased by 184USD 806,921NVCR holding decreased by -22207USD 806,921184USD -22,207 USD 11.27 USD 11.61
2025-11-05 (Wednesday)71,415USD 829,128NVCR holding decreased by -27852USD 829,1280USD -27,852 USD 11.61 USD 12
2025-11-04 (Tuesday)71,415NVCR holding increased by 185USD 856,980NVCR holding decreased by -14163USD 856,980185USD -14,163 USD 12 USD 12.23
2025-11-03 (Monday)71,230USD 871,143NVCR holding decreased by -41313USD 871,1430USD -41,313 USD 12.23 USD 12.81
2025-10-31 (Friday)71,230USD 912,456NVCR holding decreased by -713USD 912,4560USD -713 USD 12.81 USD 12.82
2025-10-30 (Thursday)71,230NVCR holding increased by 925USD 913,169NVCR holding decreased by -34542USD 913,169925USD -34,542 USD 12.82 USD 13.48
2025-10-29 (Wednesday)70,305NVCR holding increased by 370USD 947,711NVCR holding increased by 12680USD 947,711370USD 12,680 USD 13.48 USD 13.37
2025-10-28 (Tuesday)69,935USD 935,031NVCR holding decreased by -14686USD 935,0310USD -14,686 USD 13.37 USD 13.58
2025-10-27 (Monday)69,935USD 949,717NVCR holding decreased by -11889USD 949,7170USD -11,889 USD 13.58 USD 13.75
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NVCR by Blackrock for IE00BYXG2H39

Show aggregate share trades of NVCR

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY18511.27010.890 10.928USD 2,022 17.85
2025-11-06BUY18411.50011.240 11.266USD 2,073 17.92
2025-11-04BUY18512.21411.860 11.895USD 2,201 17.98
2025-10-30BUY92514.22012.725 12.875USD 11,909 18.07
2025-10-29BUY37013.48013.705 13.682USD 5,063 18.09
2025-10-22SELL-74013.86014.435 14.378USD -10,639 18.21 Profit of 2,836 on sale
2025-10-20BUY37014.48014.580 14.570USD 5,391 18.25
2025-10-17BUY92313.78014.128 14.093USD 13,008 18.28
2025-10-15BUY1,47214.18014.190 14.189USD 20,886 18.30
2025-10-03BUY1,29514.66014.690 14.687USD 19,020 18.35
2025-10-02BUY18514.05014.120 14.113USD 2,611 18.37
2025-09-30BUY37012.92013.040 13.028USD 4,820 18.43
2025-09-26BUY37012.89013.000 12.989USD 4,806 18.49
2025-09-25BUY37012.78012.840 12.834USD 4,749 18.53
2025-09-24SELL-2,33512.84013.099 13.073USD -30,526 18.56 Profit of 12,810 on sale
2025-09-18BUY19313.00013.110 13.099USD 2,528 18.59
2025-09-17BUY57912.69013.240 13.185USD 7,634 18.63
2025-08-20SELL-76811.78012.050 12.023USD -9,234 18.78 Profit of 5,191 on sale
2025-07-30BUY76410.97011.702 11.629USD 8,884 19.05
2025-07-17SELL-38216.21016.814 16.754USD -6,400 19.34 Profit of 987 on sale
2025-07-11SELL-1,52817.60018.250 18.185USD -27,787 19.40 Profit of 1,853 on sale
2025-07-07BUY57316.89017.870 17.772USD 10,183 19.44
2025-07-02BUY10,50517.88018.300 18.258USD 191,800 19.47
2025-06-20BUY1,68616.69017.070 17.032USD 28,716 19.49
2025-06-13BUY1,49817.55017.970 17.928USD 26,856 19.57
2025-06-11BUY36217.36018.560 18.440USD 6,675 19.59
2025-06-10BUY36218.38019.250 19.163USD 6,937 19.60
2025-06-04SELL-18116.72017.260 17.206USD -3,114 19.69 Profit of 450 on sale
2025-04-23BUY18117.77017.810 17.806USD 3,223 20.20
2025-04-10SELL-1,44016.08016.870 16.791USD -24,179 20.62 Profit of 5,515 on sale
2025-04-08SELL-18015.37017.190 17.008USD -3,061 20.72 Profit of 669 on sale
2025-04-07SELL-18016.61017.403 17.324USD -3,118 20.77 Profit of 621 on sale
2025-04-04SELL-90516.49016.800 16.769USD -15,176 20.82 Profit of 3,668 on sale
2025-04-01BUY75617.52018.000 17.952USD 13,572 20.90
2025-03-31SELL-54317.82018.580 18.504USD -10,048 20.93 Profit of 1,319 on sale
2025-03-21BUY3,17419.33019.500 19.483USD 61,839 21.08
2025-03-14SELL-2,73619.49020.485 20.386USD -55,775 21.20 Profit of 2,238 on sale
2025-03-07SELL-34220.18020.500 20.468USD -7,000 21.26 Profit of 270 on sale
2025-03-04SELL-17118.19018.450 18.424USD -3,151 21.37 Profit of 504 on sale
2025-02-25BUY34221.00021.400 21.360USD 7,305 21.50
2025-02-19SELL-17021.81022.200 22.161USD -3,767 21.48 Loss of -116 on sale
2025-02-13BUY51021.71021.820 21.809USD 11,123 21.42
2025-02-12BUY17021.37021.400 21.397USD 3,637 21.43
2025-02-11BUY68021.21021.660 21.615USD 14,698 21.43
2024-12-30SELL-5,67330.08030.810 30.737USD -174,371 19.71 Loss of -62,582 on sale
2024-11-18SELL-2,77515.73016.160 16.117USD -44,725 16.74 Profit of 1,720 on sale
2024-11-08SELL-18517.44018.670 18.547USD -3,431 16.61 Loss of -358 on sale
2024-10-21SELL-18616.27017.070 16.990USD -3,160 0.00 Loss of -3,160 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NVCR

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19146,2960421,75934.7%
2025-09-18109,1880560,45619.5%
2025-09-17119,469301498,06724.0%
2025-09-16191,175400705,46927.1%
2025-09-15272,06701,107,08324.6%
2025-09-12109,8570270,87440.6%
2025-09-11218,1160689,64231.6%
2025-09-10230,95395658,89035.1%
2025-09-09234,0444,681645,30736.3%
2025-09-08339,7253,440815,44541.7%
2025-09-05166,8920408,14640.9%
2025-09-04257,67243,716678,81638.0%
2025-09-03177,1140351,31950.4%
2025-09-02137,4000404,38934.0%
2025-08-29160,7270352,26345.6%
2025-08-28191,5783,553657,42329.1%
2025-08-27150,5517,255425,99235.3%
2025-08-26119,5160645,27618.5%
2025-08-25171,8120553,31531.1%
2025-08-2294,3000476,26219.8%
2025-08-21143,6200367,65139.1%
2025-08-20190,862110434,32643.9%
2025-08-19137,8590457,52230.1%
2025-08-18179,0560473,96137.8%
2025-08-15169,5698564,35130.0%
2025-08-14212,0810504,69142.0%
2025-08-13268,07401,199,25822.4%
2025-08-12212,7134,365614,71134.6%
2025-08-11194,2034512,17337.9%
2025-08-08254,9961,239736,77534.6%
2025-08-07243,762608804,78430.3%
2025-08-06229,7403,802734,19031.3%
2025-08-05463,4961,0612,536,45118.3%
2025-08-04323,99353954,16734.0%
2025-08-01378,47201,053,48535.9%
2025-07-31479,0082,5161,888,14425.4%
2025-07-30452,34501,441,40131.4%
2025-07-29329,6081,5021,070,20230.8%
2025-07-28306,60501,104,40427.8%
2025-07-25533,02442,5631,609,83133.1%
2025-07-24763,75871,5742,115,33136.1%
2025-07-23145,473921417,90734.8%
2025-07-22113,9980328,85534.7%
2025-07-21140,3120474,58129.6%
2025-07-1896,636400339,93628.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.